TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05775861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single shot interscalene brachial plexus block group with dexmedetomidine added to ropivacaine group
Description: For the single shot group with dexmedetomidine added to ropivacaine group (Group D), after local analgesia with 3 mL of 1% lidocaine, the block will be performed under ultrasound guidance using an in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany).~The perineural solution will be pre-mixed in a 30 mL syringe before the realization of the block.~A total of 150 mg of ropivacaine 0.5% will be prepared, 125 mg (25mL) will be mixed with a dose of 2 mcg/kg IBW of dexmedetomidine (100 mcg/mL dexmedetomidine hydrochloride; Precedex, Hospira Inc, Lake Forest, IL). The total of 25 mL (125 mg or ropivacaine 0.5%) with dexmedetomidine will be injected perineurally at the level of the roots and a 5 mL (25 mg) will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous interscalene brachial plexus block
Description: The block will be performed under ultrasound guidance using an in-plane approach with a 17G Tuohy needle (Arrow FlexBlock). A total of 100 mg (20 mL) of ropivacaine 0,5% will be injected perineurally at the level of the roots using the Tuohy needle. The 19 G arrow catheter will then be introduced through the Tuohy needle and we will leave 4 cm of the catheter perineurally. An additional 25 mg (5 mL) of ropivacaine 0,5% will be injected using the catheter to make sure the catheter is in a correct position. An additional 5 mL (25 mg) of ropivacaine 0.5 % will be injected between the sternocleidomastoid muscle and anterior scalene for the superficial cervical plexus block using an ultrasound in-plane approach with a 22 G 80-mm ultrasound needle (Pajunk SonoTAP II, Germany) or with a standard 25G 1 1/2 inches needle. After the surgery, an infusion of ropivacaine 0,2% at a standard rate of 5 mL/h will be started using an elastomeric pump of 300 mL (Baxter Corporation, Mississauga, Ontario).
Study: NCT05292612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT(C&W) for SAD
Description: iCBT(C\&W) for SAD implements all the key procedures of the face-to-face treatment. Patients are guided through the treatment by using secure messaging and regular telephone or webcam calls. The treatment comprises a series of online modules, each of which includes educational texts, patient testimonies, video illustrations, case examples, questionand- answer boxes, monitoring sheets, behavioural experiments and other homework assignments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT(C&W) for SAD
Description: iCBT(C\&W) for SAD implements all the key procedures of the face-to-face treatment. Patients are guided through the treatment by using secure messaging and regular telephone or webcam calls. The treatment comprises a series of online modules, each of which includes educational texts, patient testimonies, video illustrations, case examples, questionand- answer boxes, monitoring sheets, behavioural experiments and other homework assignments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT(C&W) for SAD
Description: iCBT(C\&W) for SAD implements all the key procedures of the face-to-face treatment. Patients are guided through the treatment by using secure messaging and regular telephone or webcam calls. The treatment comprises a series of online modules, each of which includes educational texts, patient testimonies, video illustrations, case examples, questionand- answer boxes, monitoring sheets, behavioural experiments and other homework assignments.
Study: NCT05271682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHND6091
Description: FHND6091 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHND6091
Description: FHND6091 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHND6091
Description: FHND6091 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHND6091
Description: FHND6091 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHND6091
Description: FHND6091 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHND6091
Description: FHND6091 capsules
Study: NCT05823337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium+ diet
Description: Selenium functions as an active site component of an antioxidant enzyme, glutathione peroxidase, and helps scavenge free radicals.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: only diet
Description: diet suitable for pregnancy
Study: NCT05762536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide 600 mg b.i.d. until the end of the last taxane cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel or cabazitaxel
Description: Docetaxel or cabazitaxel Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel or cabazitaxel
Description: Docetaxel or cabazitaxel Q3W
Study: NCT05078684

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left ganglion stellate block
Description: Ultrasound-guided anesthetic block of left ganglion stellate using 8ml of 5% bupivacaine.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham left ganglion stellate block
Description: Subcutaneous application of 0.5-1ml of 5% bupivacaine to the site of expected LGSB
Study: NCT06294444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy
Description: Group A: This group patients will be treated with mCIMT, the forced use of the affected arm by restraining the unaffected arm, with a sling or a hand splint, during dedicated exercise sections or usual ADLs (90% of waking hours).Massed practice (eight hours of exercise) of the affected arm through a shaping method, where shaping involves a commonly operant conditioning method in which a behavioural objective (in this case 'movement') is approached in small steps of progressively increasing difficulty. The participant is rewarded with enthusiastic approval for improvement, but never blamed or punished for failure. This therapy will be given 4hrs daily for 6 weeks. The results will be based upon pre and post evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: Group B: These patients will be treated with mCIMT and mirror therapy. Children were taught repetitive symmetrical upper limbs exercises: with modelling-clay in each hand to elicit bilateral thumb-finger pinch and grasping. They performed these during a 15-minute daily routine at home with mCIMT (forced use of arm and massed practice 4hrs of exercise of affected arm). This combination of therapy will be given for 6 weeks. The results will be seen through pre and post evaluation.
Study: NCT04733222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation training
Description: The treadmill perturbation training will be performed on a computer-controlled treadmill. The perturbation will be induced by fast forward (slip) or backward (trip) accelerations of the treadmill at specific gait cycle timings. The perturbations will be delivered randomly to enhance the unpredictability. A ceiling-mounted body-harness ensures the safety of the participants.~Participants will be assigned to three initial sessions of treadmill slip- and trip-perturbation training on two days separated by a week and a booster-session after six months. On day 1, participants will first undergo a session 1 with 40 slip perturbations and then a session 2 with 40 trip perturbations. On day 2, participants will undergo a session 3 with 20 slip and 20 trip perturbations in random order. The booster-session after six months will be similar to session 3 (20 of each perturbation in random order).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill walking
Description: Participants allocated to the walking group will walk at a self-selected pace on a computer-controlled treadmill for the same amount of time as the treadmill perturbation training participants.
Study: NCT05338866

Intervention type: RADIATION
Intervention: Magnetic resonance guided radiotherapy
Description: Radical radiotherapy boosting for low rectal cancer through magnetic resonance guided radiotherapy linear accelerator.

Intervention type: DRUG
Intervention: Chemotherapy
Description: For patients with AJCC stage II and III and age \< 72 years old, Capox ×6→capecitabine×2.~Detailed usage: Oxaliplatin 130mg/m2 (reduced to 100mg/m2 during concurrent chemoradiotherapy), intravenous administration, d1. Capecitabine 1000mg / m2, twice a day, d1-14. Repeated every 3 weeks.~For patients aged ≥ 72 years, or the competent physician judges that the patients cannot tolerate dual drug combined chemotherapy, capecitabine ×8 courses.~For patients with AJCC stage I, capecitabine ×4 courses.
Study: NCT04748848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle. The dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle with a brief dose ramp-up for Cycle 1 with the dosing of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Venetoclax should be administered at 400 mg on subsequent days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle with a brief dose ramp-up for Cycle 1 with the dosing of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Venetoclax should be administered at 400 mg on subsequent days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle at the recommended phase to dose of CC-90011 confirmed in dose escalation.
Study: NCT05698862

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Participants will be required to take a probiotic supplement of Lactobacillus brevis daily (1 capsule 5B CFU/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be required to take the placebo maltodextrin daily (1 capsule/day)
Study: NCT05665413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: strocking technique, HOT PACK and Ergon instrument

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: strocking technique, HOT PACK and Ergon instrument
Study: NCT05656963

Intervention type: OTHER
Intervention: Grouping based on previous laboratory results, no intervention.
Description: The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.

Intervention type: OTHER
Intervention: Grouping based on previous laboratory results, no intervention.
Description: The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.

Intervention type: OTHER
Intervention: Grouping based on previous laboratory results, no intervention.
Description: The patients were grouped according to the results of previous inpatient tests, and no intervention measures were taken.
Study: NCT06003699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Search Inside Yourself (SIY) program
Description: The present project involves the delivery of the Search Inside Yourself (SIY) program. The SIY Program is organized into 6 thematic modules. The first module introduces mindfulness and emotional intelligence and provides scientific evidence for the benefits of practicing mindfulness. The second module introduces Self-Awareness. The remaining four modules cover other domains based on Daniel Goleman's original framework of Emotional Intelligence: self-management, motivation, empathy, and leadership. Each module is associated with a set of practices, such as focused attention, body scan, journaling, empathic listening, and a Leadership Commitment exercise. The program will be delivered over 4 weeks, with one 3-hour session per week for a total of 12 hours that will take to complete all the modules.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Search Inside Yourself (SIY) program
Description: The present project involves the delivery of the Search Inside Yourself (SIY) program. The SIY Program is organized into 6 thematic modules. The first module introduces mindfulness and emotional intelligence and provides scientific evidence for the benefits of practicing mindfulness. The second module introduces Self-Awareness. The remaining four modules cover other domains based on Daniel Goleman's original framework of Emotional Intelligence: self-management, motivation, empathy, and leadership. Each module is associated with a set of practices, such as focused attention, body scan, journaling, empathic listening, and a Leadership Commitment exercise. The program will be delivered over 4 weeks, with one 3-hour session per week for a total of 12 hours that will take to complete all the modules.
Study: NCT05399615

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VOX
Description: Breath biopsy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VOX
Description: Breath biopsy
Study: NCT05694962

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Dose Radiation Therapy
Description: 1.5Gy single treatment of whole-lung radiation therapy
Study: NCT06283498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Morpheus8V
Description: Assigned to be treated using the modified Morpheus8V
Study: NCT05028036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized lifestyle treatment program
Description: The personalized treatment program is based on the participants symptom profile and test results and is designed in collaboration with the participant. The treatment plan that may include several of the following components:~* Dietary changes~* Supplements~* Measures to improve sleep / circadian rhythm~* Stress management~* Physical exercise~The treatment plan is evaluated continuously by the participant and the therapist and adjusted accordingly. A total of 9 visits to the Nordic Clinic over one year is included in the treatment program.
Study: NCT05256745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP488
Description: Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP488
Description: Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP488
Description: Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTP488
Description: Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ddAC/ddT
Description: Dose dense doxorubicin plus cyclophosphamide followed by paclitaxel (ddAC/ddT) for 8 cycles, administered per USPI (Unites States Prescribing Information) Label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC
Description: Docetaxel plus cyclophosphamide (TC) for 4-6 cycles, administered per USPI (Unites States Prescribing Information) Label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCHP
Description: Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen that includes ddAC
Description: can include: (1) weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide, administered per USPI (Unites States Prescribing Information) Label
Study: NCT05050526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time videoconference-based Exercise program
Description: 12-week exercise program consisting of two weekly 45 minute group-based sessions, remotely supervised by a professional via real-time videoconference. Each session will consist of a warm-up (5-10 min), general strengthening (30 min) and cool-down (5-10 min). Warm-up will include general joint mobility and exercises focused on increasing heart rate. General strengthening will include 4 series of 6 exercises (2 for lower limb, 2 for upper limb and 2 for the trunk) performed with minimal equipment, combining body-weight and elastic-band exercises. Three difficulty levels will be set for each of the exercises, and progression will be made at weeks 5 and 9. Participants will be asked to work in a given rate of perceived exertion (between 3 and 5 in Borg's CR10 scale) and not to reach failure in any of the exercises. Cool-down will include stretching and breathing/relaxing exercises.
Study: NCT06254300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The exercise program will consist of three sessions per week, each lasting 60 minutes. The aerobic exercise will gradually increase the duration throughout the program to 40 minutes and exercise intensity from 30% to 59% of heart rate reserve. The resistance training will include bodyweight functional exercises and resistance exercises using elastic bands. The intensity of resistance exercise will progressively increase according to levels of progressive length and resistance of the elastic bands. The volume of resistance training will start with one set of 8 repetions. It will then gradually increase alongside the program to 2 sets of 12 repetitions. Participants will also be guided to assess their subjective effort using the Borg scale (RPE 12-15).
Study: NCT06315114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lighthouse MBT Parenting Program (LPP)
Description: The experimental group is a manualized transdiagnostic mentalization-based parenting intervention (Lighthouse MBT Parenting Program). This is a 12-week parenting group intervention (weekly session of 2 hours) with one preperatory initial individual session (1 hour) before the group commence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual (CAU)
Description: 1-2 next of kin sessions (called 'Familiesamtale') is considered the care as usual offered to parents in adult mental health service in the Capital Region of Denmark.~Parents are offered the possibility of bringing their spouse or offspring to one of the sessions.
Study: NCT05930405

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: programmed intermittent epidural bolus
Description: Bolus a certain amount of liquid at fixed intervals according to a predetermined procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous epidural infusion
Description: continuous epidural infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine and sufentanil
Description: 0.15% ropivacaine and 0.4μg/ml sufentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine and sufentanil
Description: 0.15% ropivacaine and 0.4μg/ml sufentanil
Study: NCT05680324

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monsplasty
Description: liposuction assisted monsplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monsplasty
Description: liposuction assisted monsplasty
Study: NCT06509490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD-025 cell injection
Description: This is an open-label, dose escalation/expansion study to assess the safety, tolerability, and efficacy of KD-025 cell infusion in patients with advanced NKG2DL+ solid tumor. In this study,the enrollment of the patients must meet the inclusion and exclusion criteria . All subjects will be undergo screening, pre-treatment (cell product preparation;lymphodepleting chemotherapy), treatment and follow up
Study: NCT06397924

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chitin Fiber
Description: Dietary fiber isolated from an edible insect (chitin)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT06534827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Great Life Mentoring
Description: The Great Life Mentoring program (GLM) provides volunteer-based mentoring for school-age youth from low-resource families who are receiving outpatient mental health care. Each youth is paired with a mentor with whom they spend time in the community on a weekly basis for at least one year. Mentors are required to complete a 20-hour intensive training prior to being paired with a youth. Mentors also receive monthly in-person supervision from GLM staff for the first year of their meetings, which continues on an as-needed basis thereafter. Training and supervision are geared toward the unique opportunities and challenges that can occur when mentoring a youth with mental health needs. The goal is for the mentor to become an integral part of the child's mental health treatment, but the mentoring relationship is also sustained after treatment ends.
Study: NCT05239598

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mouth rinse
Description: Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouth rinse
Description: Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.
Study: NCT05216393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RecTech Match Website
Description: Participants will have access to the Rectech Match website. These participants will receive 9 health coaching calls. Fitbit physical activity data will be collected on an ongoing basis during the intervention.